PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway.
about
Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cellsVanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activityDual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatmentMetabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.Nuclear receptors in renal diseaseCellular cholesterol transport proteins in diabetic nephropathy.mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.Identifying chemokines as therapeutic targets in renal disease: lessons from antagonist studies and knockout mice.Anthocyanins inhibit high-glucose-induced cholesterol accumulation and inflammation by activating LXRα pathway in HK-2 cellsPPARs in alveolar macrophage biology.ABCA1 and atherosclerosis.The role of nuclear receptors in the kidney in obesity and metabolic syndromeEffect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.Interaction Effects of the Leu162Val PPAR α and Pro12Ala PPAR γ 2 Gene Variants with Renal Function in Metabolic Syndrome Population.Thiazolidinediones and diabetic nephropathy: need for a closer examination?PPARs and the kidney in metabolic syndrome.Systemic and renal lipids in kidney disease development and progression.PPAR-γ agonism for cardiovascular and renal protection.Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export.Role of PPARα and Its Agonist in Renal Diseases.Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells.Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts.Interleukin-32 promotes lipid accumulation through inhibition of cholesterol efflux.PPAR Medicines and Human Disease: The ABCs of It All.Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatmentLiver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells.The effects of kefir, koumiss, yogurt and commercial probiotic formulations on PPARα and PPAR-β/δ expressions in mouse kidney.Associations of genetic variants in ATP-binding cassette A1 and cholesteryl ester transfer protein and differences in lipoprotein subclasses in the multi-ethnic study of atherosclerosis.IGF-1 induces rat glomerular mesangial cells to accumulate triglyceride.Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages: the role of the peroxisome proliferator-activated receptor {gamma}-liver X receptor {alpha}-ABCA1 pathway.Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule.C1q/Tumor necrosis factor-related protein-3 protects macrophages against LPS-induced lipid accumulation, inflammation and phenotype transition via PPARγ and TLR4-mediated pathways.Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA triple knockout mice.Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro.Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.
P2860
Q24317679-5ACE6035-10D0-40AF-A143-F055C04087ADQ24322799-3FB2EC2D-D118-4B5B-AF96-6139C104E661Q24816834-B2BD4ACF-3895-4AF3-A120-73955B99E274Q27007027-6C45FEBD-56AB-476A-8068-DFBBA7D143CBQ28504786-C8318C15-1D91-41BA-ACFF-FC232F91AFA2Q28507193-E06E9785-97F4-429F-BABE-F86A443391EBQ34336370-9CF6D51E-307B-4A6F-A5AD-C35B47E0C33BQ35120702-0047234D-F904-43DE-BDD3-B3FEBE62BB27Q35236869-C114C16B-4C60-4A8C-89EB-AE572C439CFAQ35588934-1B3FA422-AA86-473A-B91A-24F696BF3B54Q35845313-38BD2C5F-7B9E-4A67-8334-333F253A5FABQ36052340-280632AC-4453-4FC6-8D59-1A1248AA5E1DQ36121727-73D81C1D-929C-48C5-B180-3D204F38ABF1Q36192289-C2943596-4AB7-4B87-8A0F-F8A96556AEE7Q36250127-F2EF85F1-E4D6-4EE0-A4C1-9604CF5582E7Q36687632-4A5EED26-1239-41DD-BEE0-485FC0302FD5Q36830957-A7FACAFF-A530-42B0-AF07-7AD948D8499EQ37024419-4A8DC9A5-1B71-43C8-8A5F-229789912FDBQ37072216-23FDB7FF-5210-478E-9701-2A334DAADE59Q37148885-B5E90EA2-B919-4DC8-8F8F-F185405688FCQ37788729-182AB62F-8EC2-45CD-978D-BBF582EA6CFBQ38546383-0D05593D-BA17-431C-8979-0AC4119D4BE0Q39440693-79ACBBE8-DA0E-48BD-B798-DACE2E795569Q39817316-29CE526D-40A3-4032-8C7E-C7C85F4593AAQ40106766-E3A71C1A-DE91-42D8-9946-764A4EDF0321Q40446287-7D5CD2B1-877F-430E-AAD1-91D3DB64B83BQ41116795-60365BCD-0FB2-40A6-AFAD-ED742FA7547FQ42214835-23938C42-4099-48AB-A0D8-9E3981B1942CQ42376328-62E47DF0-33EE-488A-8C08-E66E91727E85Q42465405-DDCCD993-94BE-4BEF-8459-3FB57ACD28ADQ44569724-2762C4D7-05BA-4462-A23D-ED83C84E06ADQ46170654-48222D54-A310-48D4-952A-6F9150AF9318Q46632303-B9A85394-3BF4-4436-87BF-89BD9C601166Q46656241-ED96F10D-3254-4949-9A7A-481F0D3F278BQ46861751-CB0FC6CB-ABA2-44F7-AAED-DA23012C98BBQ47103411-5EF63861-D35E-44AE-BC1F-C968DFA316A9Q50528684-848274F4-9466-4A49-9C3C-0C7705EAF326Q50539356-259B79EF-2D4F-4616-ADCC-A751B16B2DEDQ50703978-6864DF5B-8B04-4904-8197-2613647BB470Q52650772-2BFB12CB-14B7-46BE-BE32-4D5A6A4E4C71
P2860
PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
PPAR agonists protect mesangia ...... A1 cholesterol efflux pathway.
@en
type
label
PPAR agonists protect mesangia ...... A1 cholesterol efflux pathway.
@en
prefLabel
PPAR agonists protect mesangia ...... A1 cholesterol efflux pathway.
@en
P2093
P1476
PPAR agonists protect mesangia ...... A1 cholesterol efflux pathway.
@en
P2093
David C Wheeler
John F Moorhead
Ray Fernando
Stephen H Powis
Xiong Z Ruan
Zac Varghese
P304
P356
10.1097/01.ASN.0000050414.52908.DA
P577
2003-03-01T00:00:00Z